Researchers at Yeditepe University have developed a machine learning classifier that integrates multi-omic data and metabolic modeling, improving lung and pancreatic cancer diagnosis accuracy, according to a study in Quantitative Biology.
Read More
Illumina’s FDA-approved TruSight Oncology test will be reimbursed by CMS at $2,989.55 per test starting Jan. 1, 2026, enabling broader laboratory access to genomic profiling for Medicare beneficiaries.
Read More
The NeXT Personal molecular residual disease test can now be used for surveillance of patients with Stage I to III non-small cell lung cancer.
Read More
The CLIA-certified facility offers functional precision medicine testing that analyzes live tumor cells against FDA-approved therapies within 10 days.
Read More
PD-L1 testing is now cleared to help identify patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma who may be eligible for anti–PD-1 therapy.
Read More